OnKure Therapeutics Clinical Pipeline

Candidate Program Cand Prog	Indication Target Ind Target	Discovery HIT I.D. Discov HIT I.D.
OKI-179
	NRAS Melanoma Combo w/Binimetinib*
OKI-179	NRAS Melanoma Combo w/Binimetinib*	Nautilus Trial
Class I HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

*Supply agreement with ; OnKure retains 100% commercialization rights

Discovery

Candidate Program Cand Prog	Indication Target Ind Target	Discovery HIT I.D. Discov HIT I.D.	Phase 1 HIT to Lead Ph 1 HIT-Lead	Phase 2 Lead Optimization Ph 2 Lead Opt	Pivotal Trial IND Enabling Pivotal IND
ONK-001
	Kinase
ONK-001	Kinase
ONK-002
	Kinase
ONK-002	Kinase
ONK-003
	Kinase
ONK-003	Kinase
ONK-004
	Kinase
ONK-004	Kinase
ONK-005
	Non-Kinase Target
ONK-005	Non-Kinase Target
ONK-006
	Non-Kinase Target
ONK-006	Non-Kinase Target
ONK-007
	Degrader Target
ONK-007	Degrader Target
ONK-008
	Degrader Target
ONK-008	Degrader Target